miR-24 has been shown to attenuate mouse AMI and reduces cardiac dysfunction by inhibiting cardiomyocyte apoptosis [26]; miR-23a has been shown to positively regulate cardiac hypertrophy by targeting anti-hypertrophic factor MuRF1 [27] and Foxo3a [28]. Here, FOXO3 is linked to cardiac hypertrophy.